Rick Doblin
Rick Doblin is an American psychotherapist, researcher, and the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS). He is a prominent figure in the field of psychedelic therapy and psychedelic research, advocating for the medical and therapeutic uses of substances such as MDMA, LSD, psilocybin, and marijuana.
Early Life and Education[edit | edit source]
Doblin was born in 1953. He completed his undergraduate studies at New College of Florida and later earned a doctorate in Public Policy from Harvard University's Kennedy School of Government. His doctoral thesis focused on the medical use of psychedelic drugs.
Career[edit | edit source]
In 1986, Doblin founded the Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit research and educational organization that aims to raise awareness and understanding of psychedelic substances. MAPS conducts research into the safety and efficacy of psychedelics for treating various mental health conditions, including post-traumatic stress disorder (PTSD), anxiety, and depression.
Doblin's work with MAPS has been instrumental in advancing the field of psychedelic therapy. He has been involved in numerous clinical trials investigating the therapeutic potential of substances such as MDMA for PTSD and psilocybin for end-of-life anxiety.
Advocacy[edit | edit source]
Doblin is a vocal advocate for the reclassification of psychedelic substances, arguing that they have significant therapeutic potential that is currently underutilized due to legal restrictions. He has testified before the United States Congress and appeared in numerous media outlets to discuss the potential benefits of psychedelic therapy.
Personal Life[edit | edit source]
Doblin is known for his personal use of psychedelics and his belief in their potential to enhance personal growth and self-understanding. He has spoken publicly about his experiences with these substances and their impact on his life and work.
See Also[edit | edit source]
- Psychedelic therapy
- Psychedelic research
- Multidisciplinary Association for Psychedelic Studies
- MDMA
- LSD
- Psilocybin
- Marijuana
References[edit | edit source]
External Links[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
